 This is a Phase I, first-in-human study of a vaccine against S. mansoni infection.The study will recruit 72 healthy adult males and non-pregnant females from a single clinical center to test two formulations of Sm-TSP-2 vaccine using the Alhydrogel only, and using Alhydrogel plus GLA-AF, each at 3 different doses: 10ug, 30ug, and 100ug. The primary objective is to assess the safety and reactogenicity of ascending doses of Sm-TSP-2Alhydrogel 10ug, 30ug, or 100ug with or without GLA-AF vaccine given as three doses administered on Days 1, 57, and 113. 